The PennZone

  • Home
  • Business
  • Health
  • Education
  • Financial
  • Legal
  • Construction
  • Entertainment
  • Technology

Aclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Development of M102
The PennZone/10107057

Trending...
  • Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
  • Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
  • Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics ("Aclipse" or "the Company"), a private biopharmaceutical company, today announced that the Company and its collaborator, The Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the United Kingdom (UK), were awarded a drug development research grant of £1.6 million (approximately US $2.2 million) from the UK's Medical Research Council (MRC), one of the largest funders of medical research worldwide, to support the translational development of M102. M102 is Aclipse's drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also referred to as motor neuron disease (MND) or Lou Gehrig's disease.

M102 is a potentially disease-modifying drug candidate that has shown promise to impede ALS disease progression in a wide array of preclinical models. Currently, there is no cure for ALS and there are no effective treatments to halt or slow the progression of the disease.

"This development funding from MRC is wonderful news for ALS/MND patients who are in dire need of an effective therapy to address this life-threatening neurodegenerative disease," stated Professor Dame Pamela Shaw, M.D., Director of SITraN and a primary contributor to M102's development program. "Along with my SITraN colleagues, Dr. Richard Mead and Dr. Laura Ferraiuolo, we spearheaded the ALS/MND biology research that led to the development of M102, including the discovery of a potential precision medicine approach for M102 in ALS/MND, so we are very appreciative of MRC's funding support."

Aclipse is taking a multiple biological pathway, multiple disease mechanism approach to ALS. M102 activates the NRF2 (nuclear factor erythroid 2-related factor 2) and HSF1 (Heat shock factor 1) signaling pathways, which are recently understood to impact ALS pathophysiology. M102 is expected to be mechanistically superior to currently available drugs and may lead to significant slowing of disease progression in both familial and sporadic ALS.

More on The PennZone
  • Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
  • Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
  • Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • Franchise-Ready: Wise Business Plans Partners with Leading Franchisors to Support New Franchisees

The MRC grant will also support the development of patient stratification biomarkers that will be applied in the M102 clinical studies, potentially enabling a personalized medicine approach in ALS. The goal of the patient stratification biomarkers is to identify M102 drug responders versus non-responders in order to target M102 to those ALS patients most likely to benefit from the drug.

"We greatly appreciate the support from MRC for our novel and broad multi-disease patho-mechanism approach to treating ALS patients," said Raymond K. Houck, CEO of Aclipse Therapeutics. "The MRC award, coupled with our recent FightMND grant award, accelerates M102's development into its first-in-human clinical studies and validates M102's biology and potential for a precision medicine approach for the treatment of ALS."

"The research funding from these programs will be key as they will support the completion of our investigational new drug (IND)-enabling work and the regulatory filings for first-in-human studies. Importantly, M102 may have applications in a wide array of conditions associated with impaired neuronal function such as Friedreich's ataxia, Huntington's disease and Parkinson's disease," added Mr. Houck.

About ALS/MND
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a progressive neurodegenerative disease that affects motor neurons (nerve cells) in the brain and the spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within two to five years of diagnosis. There is no cure and limited life-prolonging treatments for the disease. Based on U.S. population studies, approximately 5,600 people in the U.S. are diagnosed with ALS each year and as many as 25,000 Americans have the disease at any given time.

About Medical Research Counsel

More on The PennZone
  • VIP Vacations Recognized as a 2024 Top Selling Travel Agency by the Jamaica Tourism Board
  • Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025

The United Kingdom's Medical Research Counsel's mission is to improve human health through world-class medical research. To achieve this, MRC supports research across the biomedical spectrum, from fundamental lab-based science to clinical trials, and in all major disease areas. MRC works closely with the UK's National Health Service and the UK Health Departments to deliver its mission and give a high priority to research that is likely to make a real difference to clinical practice and the health of the population.

About the Sheffield Institute for Translational Neuroscience
The Sheffield Institute for Translational Neuroscience (SITraN) is an international center of excellence recognized for its ground-breaking work in the fight against motor neurone disease and other common neurodegenerative disorders. SITraN brings together 300 staff and research students in multi-disciplinary teams with state-of-the-art laboratories and equipment to study neurological illness. The center is unique in its design to unite clinicians and multidisciplinary teams of scientists to translate discoveries in basic neuroscience into benefits for patients. The SITraN teams have developed a robust portfolio of in vitro and in vivo models to facilitate our understanding of disease mechanisms and identify new targets for therapeutic intervention which can be tested in our BRC experimental medicine programs.

The work of SITraN is a major pillar of the University of Sheffield's cross-faculty Neuroscience Institute, one of four flagship research institutes launched in 2019 to tackle the biggest global challenges through pioneering real-world solutions and involving >120 principal investigators in the Faculties of Medicine, Science and Engineering.

About Aclipse Therapeutics
Aclipse Therapeutics develops novel and differentiated drugs to treat orphan diseases with significant unmet medical needs. Our lead drug candidate, M102, is in development for the treatment of ALS with potential use in other neurodegenerative diseases such as Friedreich's ataxia, Huntington's disease and Parkinson's disease. M102 targets multiple disease pathomechanisms and enables a precision medicine approach for the identification of patients who are most likely to benefit from the drug. Aclipse has a very experienced orphan drug management team and a clinical advisory board of the top ALS physicians in the world. For more information about Aclipse, visit the website at https://www.aclipsetherapeutics.com or email info@aclipsetherapeutics.com.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Abide Capital Acquires Columbus, OH Apartment Community for $16.5 Million
  • Miami Real Estate Agent Drastically Increases Interest In Homes
  • Adostics & Genmega Announce the Introduction of A-POD
  • QVC Kicks Off 'Christmas in July' with Star-Studded Merrymakers Lineup: Elton John, Martha Stewart, Kathy Hilton, Kim Gravel and Babs Costello as Chief Cheer Officer
  • LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
  • Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
  • INVESTIGATION ALERT: Berger Montague PC Investigates Aflac, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: AFL)
  • The Waite Launches: A Curated Motherhood Marketplace For Every Stage
  • Affordable, High-Quality Care: Cheap Braces for Adults Available from Exeter Smiles in Reading
  • NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
  • Sci-Fi Novel from Pittsburgh Author Explores Love, Power, & Humanity in an Age of Artificial People
  • Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
  • Greenlight Networks to Acquire Loop Internet
  • Finding the Best AC Repair Service in Philadelphia
  • Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
  • BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
  • Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
  • Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
  • Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
  • Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy

Popular on PennZone

  • INVESTIGATION ALERT: Berger Montague PC Investigates Coinbase Global, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NASDAQ: COIN)
  • Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
  • New Bethany Acquires Former Diocesan Headquarters to Expand Services
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • Bethany Nikitenko Honored By Legal Intelligencer with Power Player Award
  • Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
  • JOSHWAY Launches Children's Book, "JOSHWAY and the Power of Resilience"
  • OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook
  • Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
  • KeysCaribbean Vacation Home Rentals Offers Last-Minute Booking Discount of 15 Percent

Similar on PennZone

  • Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
  • The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
  • Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • Franchise-Ready: Wise Business Plans Partners with Leading Franchisors to Support New Franchisees
  • CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025
  • Federated Hermes Premier Municipal Income Fund declares dividend
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us